CONFERENCE DAY ONE LIVE
8.00 am Registration & Coffee
8:45 am Chair’s Opening Remarks
Improving Patient Outcomes of Next-Generation Bacteriophage Therapy
9:00 am Shedding Light on Success of Bacteriophage Clinical Trials on Humans
Synopsis
- Demonstrating clinical safety and efficacy of phage therapy in patients with cystic fibrosis
- Unpicking positive results from clinical data on chronic pulmonary infections to expand pipeline progress
- Advancing clinical trials to the next steps to optimize final success of combating P. aeruginosa
9:30 am Advancing Phage-Based Therapies Towards Clinical Studies
Synopsis
- Revealing clinical data highlights from unblinded stage of phage-led study
- Implementing insights to ongoing Phase II trial for blinded study on patients to treat UTIs
- Targeting population to improve patient recruitment and health outcomes during clinical trials
10:00 am Advanced Phage Profiling to Guide Therapeutic Development & Inform Drug Discovery Pipelines
Synopsis
- Virome profiling based on the most extensive virus database available to enable detection of more than 64,000 virus species (vOTUs)
- Superior Accuracy: Demonstrates significant advancements over other pipelines in benchmarking studies and detects a broader range of phage species with nearly zero false positives
- Phage Behavior Insights: Provides detailed annotations on phage lifestyles and precise host mapping to enhance understanding of phage-bacterial interactions
10:30 am Morning Refreshments & Speed Networking
11:30 am Management of Diabetic Foot Infections Using Phage Products: Unveiling TP-102 Phase IIb Study
Synopsis
- Articulating regulatory challenges in phage development to enable treatment of human disease
- Showcasing design of clinical trial protocol for safe and effective Phase IIb phage product
- Highlighting critical findings of phage therapy to treat diabetic foot infections from preliminary results
12:00 pm Armata Clinical Trials Overview of Bacteriophage Administration for Difficult-to-Treat Infections
Synopsis
- Value of a phage cocktail approach in subjects with chronic pseudomonal respiratory infections
- Similarities of phage distribution and phage kinetics between cystic fibrosis and non-cystic fibrosis bronchiectasis subjects administered nebulized phage (AP-PA02)
- Purity of high dose S. aureus phage (AP-SA02) and ability to safely dose escalate intravenously over multiple days in subjects with S. aureus bacteremia
12.30 pm Lunch & Networking
Innovating in Phage Technology & Artificial Intelligence to Enhance Efficacy Profile
1:30 pm Lessons Learned from Google: Applying AI in Practice for Development & Production of Bacteriophage
Synopsis
- Understanding the variations in machine learning (supervised, unsupervised, self-supervised) for application of AI
- Unveiling the benefits of implementing AI to provide a clearer direction for therapeutic phage use
- Selecting optimal data and algorithms to overcome common pitfalls when leveraging AI and bioinformatics
2:00 pm Gaining Insights into Clinical Testing of Engineered Phage Cocktail Targeting E. coli
Synopsis
- Revealing clinical results from Phase I trial on orally dosed, CRISPR-armed phage designed for precision killing of E. coli
- Improving safety, tolerability, and microbiological efficacy endpoints for superior patient results
- Consolidating the next steps in development and success of CRISPR-led phage therapy
2.30 pm Afternoon Refreshments & Poster Session
3:15 pm Discovering, Purifying & Selecting the Appropriate Cocktail Phage for Personalized Medicine
Synopsis
- Integrating bioinformatics to determine safety and efficacy of phage in humans
- Creating lab-based solutions for individual phage development and production for higher specificity
- Establishing phage pipeline to delve into medical, pharmaceutical, and regulatory achievements
Streamlining Manufacturing Processes for Bacteriophage Commercialization
3:45 pm Process Monitoring & Controlling Critical Process Parameters to Obtain Higher Phage Yields in Upstream & Downstream Manufacturing
Synopsis
- Understanding the use of online sensors for upstream production of phage in stirredtank bioreactors
- Delving into the modelling and optimization of upstream production of phage products
- Highlighting downstream processing of phage using tangential flow filtration and chromatography – leveraging MALDI-TOF, MADLS, and other analytical approaches forcharacterizing phage drug substance and linking critical process parameters with critical quality attributes